Serum chromogranin A in the control of patients on long-term treatment with inhibitors of acid secretion

European Journal of Clinical Investigation

Volumn 31, Issue 9, 2001, Pages 741-743

  Waldum, H L ^a,b   Syversen, U ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; ENZOMAPRAZOLE; GASTRIN; GASTRIN RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN; OMEPRAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

BLOOD LEVEL; CARCINOGENESIS; ENTEROCHROMAFFIN CELL; GASTRECTOMY; GASTRIN CELL; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; LONG TERM CARE; NEUROENDOCRINE TUMOR; NONHUMAN; NOTE; PEPTIC ULCER; PERNICIOUS ANEMIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REFLUX ESOPHAGITIS; STOMACH ACID SECRETION; STOMACH CARCINOMA; STOMACH PH;

ANTI-ULCER AGENTS; BIOLOGICAL MARKERS; CHROMOGRANIN A; CHROMOGRANINS; GASTRIC ACID; HUMANS; HYPERPLASIA; STOMACH DISEASES;

EID: 0035726546     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2001.00889.x     Document Type: Note

References (42)

1. Helicobacter pylori and peptic ulcer disease
2. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori
3. Oesophagitis, signs of reflux and gastric acid secretion in patients with symptoms of gastroeseophageal reflux disease
4. Natural history of reflux oesophagitis: A 10 year follow up of its effect on patient symptomatology and quality of life
5. The rationale for continuous maintenance treatment of reflux esophagitis
6. Heartburn without oesophagitis. Efficacy of omeprazole therapy and features determining therapeutic response
7. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. The Esomeprazole Study
8. Effect of once daily intravenous and oral omeprazole on 24-hour intragstric acidity in healthy subjects
9. pH dependence of acid secretion and gastrin release in normal and ulcer subjects
10. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole
11. Long-term treatment with omeprazole for refraxtory reflux esophagitis. Efficacy and safety
12. Gastrin produdces an immediated and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach
13. Histamine secretion from rat enterochromaffin-like cells
14. Cloning and characterization of gastrin receptor from ECL carcinoid tumor of mastomys natalensis
15. The CCK-2 receptor is located on the ECL cell, but not on the parietal cell
16. Regulation of parietal cell calcium signaling in gastric glands
17. Correlation between serum gastrin concentration and rat stomach histidine decarboxylase activity
18. Gastrin regulates histidine decarboxylase activity and mRNA abundance in rat oxyntiv mucosa
19. Serum gastrin concentration affects the self replication rate of the enterochromaffin-like cells in the rat stomach
20. Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: A study by elutriation centrifugation
21. Trophic effect of gastrin on the interochromaffin-like cells of the rat stomach: Establishment of a dose-response relationship
22. Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat
23. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion
24. 2 blockade
25. Long-term effects of reduced gastric avidity in laboratory animals
26. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer
27. Species variations in gastric toxicity following chronic administration of ciprofibrate to rat, mouse and marmoset
28. The peroxisome proliferator ciprofibrate induces hypergastrinemia without raising gastric pH
29. Gastric argyrophil carcinoidosis in patients with Zollinger Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association
30. Clinical and histopathological tumour progression in ECL cell carcinoids ('ECLomas')
31. Neuroendocrine differentiation in gastric adenocarcinomas associated with servere hypergastrinemi
32. Are diffuse gastric carcinomas neuroendocrine tumours (ECL-omas)?
33. Neuroendocrine differentiation in human gastric carcinoma
34. Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique
35. Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon
36. Histamine in endocrine cells of the stomach. A survey of several species using a panel of histamine antibodies
37. Ultrastructural localization of chromogranin: A potential marker for the electron microscopical recognition of endocrine cell secretory granules
38. Evidence that rat stomach ECL cell represent the main source of circulating pancreastatin
39. Marked increase in gastric avid secretory capacity after omeprazole treatment
40. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy
41. Hypergastrinemia as a cause of chromogranin A (CgA) increase in blood in patients suspected to have neuroendocrine tumor
42. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients